Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Jonathan Graham

Health Solutions

United States

Research Interests

Explore related searches

Professors in United States

Articles (10)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (5)

Frederik Verelst

BELGIUM

View details

Mei Grace

Health Solutions

UNITED STATES

View details

David Singer

GlaxoSmithKline

UNITED STATES

View details

Justin Carrico

GlaxoSmithKline (United States)

UNITED STATES

View details

Katherine Hicks

Health Solutions

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jonathan Graham

Research Interests

Explore related searches

Articles (10)

Cost-effectiveness of the adjuvanted respiratory syncytial virus prefusion F protein (RSVPreF3) vaccine in Japanese adults aged 50–59 years at increased risk of severe RSV disease and those aged ≥60 years

Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease

Public Health Impact and Cost-Effectiveness of Revising the Adolescent Meningococcal Vaccine Schedule in the United States

Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States

Market and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA

Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination among Adults in the USA Aged 50–59 Years at Increased Risk of Severe RSV Disease

Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season

EE134 Public health impact and cost-effectiveness of adjuvanted RSVPREF3 vaccination in us adults aged 60 years with cardiopulmonary disease

EE21 Estimated public health impact of adjuvanted RSVPREF3 vaccination in us adults aged 18-49 years who are at increased risk for severe RSV disease

Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in U.S. adults aged ≥60 years with diabetes

Collaborators (5)

Frederik Verelst

Mei Grace

David Singer

Justin Carrico

Katherine Hicks

Make your next move.